10-Q: MDB Capital Holdings Reports Q3 2024 Results: Operating Losses Widen Amidst Increased Expenses

MDB Capital Holdings reported a net loss of $8.4 million for the third quarter of 2024, driven by increased operating costs and unrealized losses on investment securities.

Summary

• MDB Capital Holdings reported a net loss of $8.4 million for the three months ended September 30, 2024, compared to a net loss of $3.2 million for the same period in 2023.
• The company's operating loss for the quarter was $8.7 million, significantly higher than the $3.3 million loss in the prior year.
• For the nine months ended September 30, 2024, the net loss was $20.9 million, compared to a net loss of $1.8 million for the same period in 2023.
• Operating costs increased substantially, with general and administrative costs rising to $7.4 million in Q3 2024 from $2.5 million in Q3 2023, and research and development costs also increasing significantly.
• The company experienced unrealized losses on investment securities of $718,491 in Q3 2024, compared to a loss of $786,906 in Q3 2023.
• Fee income was absent in Q3 2024, compared to $0 in Q3 2023, while other operating income increased to $104,246 from $11,502.
• Interest income increased to $279,125 in Q3 2024 from $176,300 in Q3 2023.
• The company's cash and cash equivalents stood at $16.7 million as of September 30, 2024, compared to $6.1 million at the end of 2023.
• Total assets decreased to $34.2 million as of September 30, 2024, from $43 million at the end of 2023.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses and increasing expenses. While there are some positive aspects like increased cash, the overall sentiment is negative due to the poor financial performance and internal control issues.

Positives

• Cash and cash equivalents increased significantly to $16.7 million, providing a stronger liquidity position.
• Other operating income increased substantially to $104,246 in Q3 2024, compared to $11,502 in Q3 2023.
• Interest income rose to $279,125 in Q3 2024, up from $176,300 in Q3 2023.

Negatives

• The net loss significantly increased to $8.4 million in Q3 2024, compared to $3.2 million in Q3 2023.
• Operating costs more than tripled to $8.1 million in Q3 2024, compared to $2.5 million in Q3 2023.
• The company experienced a $718,491 unrealized loss on investment securities in Q3 2024.
• Fee income was absent in Q3 2024, compared to $0 in Q3 2023.
• Total assets decreased to $34.2 million as of September 30, 2024, from $43 million at the end of 2023.

Risks

• The company's increasing operating costs and net losses raise concerns about its financial sustainability.
• Unrealized losses on investment securities could continue to negatively impact the company's financial performance.
• The company's reliance on investment banking fees and the volatility of those fees could pose a risk to revenue stability.
• The company's technology development segment is subject to the risks of research and development, and the success of these projects is not guaranteed.
• The company's internal controls have been identified as having material weaknesses, which could impact the reliability of financial reporting.

Future Outlook

Invizyne anticipates completing its initial public offering, which is expected to close on November 14, 2024, with trading expected to have begun on November 13, 2024. This offering will reduce MDB Capital Holdings ownership stake from approximately 61% to 49%.

Management Comments

• The company is implementing measures designed to ensure that control deficiencies contributing to the previously disclosed material weakness are remediated.
• The company has redesigned the financial reporting process, to remediate the previously identified material weakness.
• The company expects these changes to materially improve its internal controls.

Industry Context

The company operates in the financial services and biotechnology sectors, which are both subject to significant market volatility and regulatory scrutiny. The increased operating costs and net losses may be concerning to investors, especially in the current economic climate. The upcoming IPO of Invizyne is a significant event that could impact the company's future performance.

Comparison to Industry Standards

• MDB Capital Holdings' performance is significantly below industry standards for profitability, as evidenced by the large net losses and increasing operating costs.
• Compared to other broker-dealers, MDB's fee income is low, and its reliance on investment banking fees makes it vulnerable to market fluctuations.
• The company's research and development expenses are high compared to other companies in the biotechnology sector, which may indicate a higher risk profile.
• The company's cash position is relatively strong, but its negative earnings and increasing expenses raise concerns about its long-term financial health.
• The company's internal control weaknesses are a significant concern, as they could impact the reliability of financial reporting and investor confidence.

Related Party Transactions

• The principal members of the Company have a controlling interest in MDB Capital, S.A., a company organized and based in Nicaragua that provides outsourced services to the Company.
• During the nine-months ended September 30, 2024 and 2023, the Company paid $1,115,200 and $829,474, respectively, for contracted labor from MDB Capital, S.A.
• PatentVest engaged in transactions with ENDRA Life Sciences Inc, a company for which two of our executive officers serve as board members.
• The customer liability account balances include a total of $51,297, which is comprised of funds from executives, board members, and the children of the broker-dealers leadership.

Stakeholder Impact

• Shareholders will be concerned about the significant net losses and increasing operating costs.
• Employees may be affected by the company's financial performance and any potential cost-cutting measures.
• Customers of the broker-dealer may be impacted by any changes in the company's financial stability.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.
• The upcoming IPO of Invizyne will impact the ownership structure of MDB Capital Holdings.

Next Steps

• The company is focused on remediating the material weaknesses in internal control over financial reporting.
• The company is preparing for the upcoming IPO of Invizyne.
• The company will continue to monitor market conditions and adjust its business plans as needed.

Key Dates

Keywords

MDB Capital Holdings, financial results, quarterly report, net loss, operating costs, investment securities, broker-dealer, intellectual property, technology development, Invizyne, financial performance